GMED icon

Globus Medical

56.75 USD
+0.53
0.94%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
56.65
-0.10
0.18%
1 day
0.94%
5 days
-4.7%
1 month
-5.81%
3 months
-1.08%
6 months
-20.73%
Year to date
-30.65%
1 year
-18.45%
5 years
10.99%
10 years
129.85%
 

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Employees: 5,300

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,135% more call options, than puts

Call options by funds: $34M | Put options by funds: $1.52M

30% more repeat investments, than reductions

Existing positions increased: 194 | Existing positions reduced: 149

6% less funds holding

Funds holding: 508 [Q1] → 477 (-31) [Q2]

10.76% less ownership

Funds ownership: 94.97% [Q1] → 84.2% (-10.76%) [Q2]

16% less capital invested

Capital invested by funds: $8B [Q1] → $6.73B (-$1.27B) [Q2]

17% less funds holding in top 10

Funds holding in top 10: 18 [Q1] → 15 (-3) [Q2]

27% less first-time investments, than exits

New positions opened: 67 | Existing positions closed: 92

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$66
16% upside
Avg. target
$75
32% upside
High target
$90
59% upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Wells Fargo
Vik Chopra
$66
Overweight
Maintained
8 Aug 2025
Canaccord Genuity
William Plovanic
$90
Buy
Maintained
22 Jul 2025
Morgan Stanley
Drew Ranieri
$68
Overweight
Maintained
15 Jul 2025

Financial journalist opinion

Based on 3 articles about GMED published over the past 30 days

Positive
Zacks Investment Research
6 days ago
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
Negative
Zacks Investment Research
14 days ago
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
Neutral
GlobeNewsWire
21 days ago
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc.
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
Positive
Zacks Investment Research
1 month ago
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
Neutral
Seeking Alpha
1 month ago
Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian J. Kearns - Senior Vice President of Business Development & Investor Relations David C.
Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Globus Medical (GMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Positive
Zacks Investment Research
1 month ago
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
Neutral
The Motley Fool
1 month ago
Globus Medical (GMED) Q2 Revenue Up 18%
Globus Medical (GMED) Q2 Revenue Up 18%
Globus Medical (GMED) Q2 Revenue Up 18%
Neutral
GlobeNewsWire
1 month ago
Globus Medical Reports Second Quarter 2025 Results
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.
Globus Medical Reports Second Quarter 2025 Results
Positive
Zacks Investment Research
1 month ago
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Charts implemented using Lightweight Charts™